Zoetis Inc. $ZTS Shares Acquired by Citizens National Bank Trust Department

Citizens National Bank Trust Department grew its holdings in Zoetis Inc. (NYSE:ZTS) by 19.8% in the 2nd quarter, HoldingsChannel reports. The firm owned 8,119 shares of the company’s stock after purchasing an additional 1,341 shares during the quarter. Citizens National Bank Trust Department’s holdings in Zoetis were worth $1,266,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. Nuveen LLC purchased a new position in Zoetis in the first quarter valued at $616,375,000. Mackenzie Financial Corp boosted its stake in shares of Zoetis by 4,158.3% in the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock valued at $300,481,000 after buying an additional 1,782,110 shares during the period. Sarasin & Partners LLP purchased a new position in shares of Zoetis in the 1st quarter valued at about $255,842,000. Polen Capital Management LLC grew its position in shares of Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after buying an additional 1,313,653 shares in the last quarter. Finally, Amundi increased its stake in shares of Zoetis by 30.8% during the first quarter. Amundi now owns 3,595,628 shares of the company’s stock worth $575,691,000 after buying an additional 846,909 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on ZTS. Argus reiterated a “buy” rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research report on Saturday, September 27th. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and cut their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Piper Sandler upped their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Five investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Zoetis currently has an average rating of “Moderate Buy” and an average target price of $200.88.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $142.91 on Wednesday. The company’s fifty day moving average price is $149.52 and its 200 day moving average price is $154.82. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $196.55. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a market capitalization of $63.33 billion, a P/E ratio of 24.60, a P/E/G ratio of 2.33 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.